What is the current evidence supporting atherectomy devices and what are the current indications for use of each type of atherectomy device in the peripheral arterial system?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Current Evidence and Indications for Atherectomy in Peripheral Arterial Disease

Atherectomy should NOT be used routinely in peripheral arterial interventions—current evidence does not support superior long-term patency or limb salvage compared to balloon angioplasty or stenting, but it has a selective role as a vessel preparation tool in heavily calcified lesions, undilatable stenoses, in-stent restenosis, and when bailout stenting must be avoided 1, 2.

Evidence Quality and Strength

The 2018 ACC/AHA/SCAI/SIR/SVM Appropriate Use Criteria explicitly rated atherectomy as "Rarely Appropriate" in iliac arteries due to absence of comparative data versus balloon angioplasty and stenting 1. For femoropopliteal and below-the-knee vessels, atherectomy received lower appropriateness scores because of lack of comparative evidence relative to technologies with prospectively collected data 1.

The most comprehensive recent meta-analysis (2025) of 322 published studies found favorable procedural outcomes but acknowledged considerable heterogeneity and emphasized the need for appropriate comparative studies 3. The 2020 Cochrane systematic review concluded with very low-certainty evidence that atherectomy shows no clear difference versus balloon angioplasty in 6-month patency (RR 1.06,95% CI 0.94-1.20), 12-month patency (RR 1.20,95% CI 0.78-1.84), or mortality 4.

Procedural Advantages (Not Long-Term Benefits)

Atherectomy consistently demonstrates:

  • Greater luminal gain at lower inflation pressures
  • Fewer flow-limiting dissections (RR 0.28,95% CI 0.14-0.54) 4
  • Reduced bailout stenting (RR 0.26,95% CI 0.09-0.74) 4
  • Improved vessel compliance for subsequent drug-coated balloon delivery 2, 5

These are preparation advantages, not durability benefits—randomized trials have not shown superior long-term patency or limb salvage 2, 4.

Device-Specific Indications

Rotational Atherectomy

  • Heavily calcified femoropopliteal lesions requiring debulking
  • Long-segment occlusions where stenting is undesirable
  • Preparation before drug-coated balloon application in calcified vessels

Directional Atherectomy

  • Eccentric plaque in femoropopliteal segments
  • In-stent restenosis where additional metal should be avoided
  • Mobile arterial segments (popliteal) where stent fracture risk is high

Orbital Atherectomy

  • Circumferential heavy calcification in femoropopliteal arteries
  • Long calcified lesions requiring uniform debulking
  • Below-the-knee calcified vessels (use with extreme caution due to higher complication rates) 6

Laser Atherectomy (355-nm)

  • In-stent restenosis and occlusions
  • Chronic total occlusions requiring crossing facilitation
  • Below-the-knee interventions in selected cases 7

Anatomic Location-Specific Guidance

Iliac Arteries: Avoid

Use balloon angioplasty with selective stenting. Atherectomy is Rarely Appropriate per 2018 guidelines 1.

Femoropopliteal Arteries: Selective Use

Reserve for:

  • Severe calcification preventing balloon expansion
  • Undilatable lesions after high-pressure balloon failure
  • In-stent restenosis
  • Long lesions (>100mm) where minimizing metal is critical
  • Preparation before drug-coated balloon in calcified vessels 1, 2

Below-the-Knee: Use Sparingly

Evidence is weakest here. Consider only for:

  • Severe calcification preventing balloon expansion
  • Undilatable lesions in critical limb-threatening ischemia
  • Accept higher complication rates (distal embolization 2.2% across studies) 3, 6

Critical Caveats

Distal embolization risk: Meta-analysis shows 2.2% rate across 159 studies 3. The Cochrane review found increased embolization events (RR 2.51,95% CI 0.64-9.80) though not statistically significant 4. Use distal protection when feasible in high-risk scenarios.

Cost without proven benefit: Given expense and lack of long-term superiority, the 2018 guidelines explicitly recommend further comparative investigation before routine use 1.

Operator experience matters: The 2023 ACC/AHA/SCAI training statement emphasizes trainees should understand when atherectomy is necessary for lesion preparation, implying selective rather than routine application 8.

Practical Algorithm

  1. First-line: Balloon angioplasty ± drug-coated balloon
  2. If undilatable after high-pressure balloon: Consider atherectomy OR intravascular lithotripsy
  3. If severe calcification anticipated: Consider intravascular lithotripsy first (safer profile) 7
  4. If in-stent restenosis: Directional or laser atherectomy to avoid additional metal
  5. If mobile segment (popliteal): Atherectomy preferred over stenting to avoid fracture risk

The responsible use of atherectomy requires integration of available evidence with operator expertise, awareness of alternative technologies (especially intravascular lithotripsy), and consideration of procedural risks 2.

References

4
Research

Atherectomy for peripheral arterial disease.

The Cochrane database of systematic reviews, 2020

6
Research

The Role of Atherectomy in the Treatment of Peripheral Artery Disease.

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2026

7
Research

Advances in Endovascular Therapy for Infrainguinal Peripheral Arterial Disease: Devices and Outcomes.

The International journal of angiology : official publication of the International College of Angiology, Inc, 2026

Related Questions

In a patient with mildly elevated liver enzymes (GGT 186 U/L, AST 35 U/L, ALT 67 U/L), which psychotropic medications are preferred?
For a pediatric patient (33 kg) with methicillin‑susceptible Staphylococcus aureus (MSSA) osteomyelitis, after increasing vancomycin from 500 mg every 6 hours to 750 mg three times daily, what is the optimal steady‑state trough concentration to target when area‑under‑the‑curve (AUC) cannot be calculated?
In a woman who is five weeks pregnant with severe pain unresponsive to acetaminophen, is it appropriate to prescribe morphine while avoiding tramadol?
What is the significance of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in reactive arthritis?
Can rapid acceleration or sudden changes in G‑force cause hearing loss, barotrauma, or vestibular dysfunction?
What should an RN document in the postoperative chart for an elderly patient (>65 years) after hip fracture surgery, including surgery details, vitals, pain scores, incision assessment, neurovascular status, anticoagulation, weight‑bearing orders, fall precautions, medication administration, and any abnormal findings?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.